Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Tatyana Feldman, MD, Larysa Gromko, MD, Ewelina A Protomastro, MS, Lina Starovoitova, BS, Anthony R. Mato, MD MSCE, Chad Glisch, Mona Sadekh, MD, Benjamin Schoener, MD, Susan Stives, APN, Marisa Valentinetti, RN, Mary Timberg, APN, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Xiao Yang, MD PhD, Alan P Skarbnik, MD, Andre Goy, MD MS

Blood (2014) 124 (21): 1307.

https://doi.org/10.1182/blood.V124.21.1307.1307

Published: 2014

Journal Articles

Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL)

Christina Howlett, PharmD, Andre Goy, MD, Tania Zielonka, Andrew L Pecora, MD, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L. Donato, MD, Mary Timberg, MSN, Gabriella Gadaleta, MSN, David H. Vesole, MD, PhD, Pritish M Bhattacharyya, MD, Kar Fai Chow, MD, Raihan Faroqui, BS, Maria Rosario, Anthony R Mato, MD, MSCE

Blood (2013) 122 (21): 2141.

https://doi.org/10.1182/blood.V122.21.2141.2141

Published: 2013

Journal Articles

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Tatyana Feldman, MD, Anthony R Mato, MD, Michele L. Donato, MD, Scott D Rowley, MD, Stuart L. Goldberg, MD, Carolanne Carini, RN, Marisa Valentinetti, RN, Judith Smith, RN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Susan Stives, APN, Mary Timberg, RN, MSN, OCN, NP-C, Ewelina A Protomastro, BA, Joshua R. Richter, MD, David H. Vesole, MD, PhD, Andrew L Pecora, MD, David S. Siegel, MD, PhD, Andre Goy, MD

Blood (2012) 120 (21): 3710.

https://doi.org/10.1182/blood.V120.21.3710.3710

Published: 2012

Journal Articles

Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.

Anthony R Mato, MD, Kathryn Waksmundzki, BS, Tania Zielonka, RDC, Ewelina A Protomastro, BA, Theresa Amatucci, BS, Maria Rosario, Stuart L. Goldberg, MD, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L. Donato, MD, Mary Timberg, RN, MSN, OCN, NP-C, Melissa F Baker, APN, Pam Sutherland, MSN, CRNP, Phyllis McKiernan, MSN, CRNP, Andrew L Pecora, MD, Andre Goy, MD

Blood (2012) 120 (21): 3120.

https://doi.org/10.1182/blood.V120.21.3120.3120

Published: 2012

Journal Articles

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Anthony R Mato, MD, Ewelina A Protomastro, BA, Tania Zielonka, RDC, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Pritish K. Bhattacharyya, MD, Mary Timberg, RN, MSN, OCN, NP-C, Susan Stives, APN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Andre Goy, MD

Blood (2012) 120 (21): 3658.

https://doi.org/10.1182/blood.V120.21.3658.3658

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL)

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy

Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL)

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center.

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only